MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $53.68M rose 173.6% year over year, ahead of the +136.8% change in trailing-twelve-month research & development. Sequentially, it fell 16.7% from the prior quarter. Over 3 fiscal years it compounded at +73.1% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +173.6% holds above the trailing-twelve-month pace of +136.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 137.77M USD
- Year-over-year change
- +103.1%
- 3-year CAGR
- +73.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 137.77M | +103.1% |
| FY2024 | 2024-12-31 | 67.82M | +38.1% |
| FY2023 | 2023-12-31 | 49.12M | +84.9% |
| FY2022 | 2022-12-31 | 26.57M | — |
Research & Development vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's LTM Mar 2026 research & development of $171.97M is the 2nd highest of the 11 companies compared; the peer median is $49.61M.
- Its year-over-year change of +136.8% is the 2nd highest of 10, against a peer median of +19.0%.
- Over three fiscal years its annual growth of +73.1% compares with a peer median of +21.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $5.27B | +80515.8% | -26.7% | — | |
| LTM Mar 2026 | $171.97M | +136.8% | +73.1% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $169.81M | +60.3% | +48.2% | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $162.51M | -21.6% | +18.9% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.93M | +58.7% | +118.3% | 539.7% |
| LTM Mar 2026 | $55.94M | +19.0% | +24.4% | — | |
| LTM Mar 2026 | $43.27M | +26.5% | +23.7% | — | |
| LTM Dec 2025 | $31.8M | -27.0% | -0.3% | — | |
| LTM Mar 2026 | $30.07M | -8.9% | +1.3% | 422.2% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $28.47M | — | +131.7% | — |
| LTM Mar 2026 | $13.88M | -59.9% | -13.7% | 11.3% | |
| Peer median (excluding MPLT) | $49.61M | +19.0% | +21.3% | 422.2% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 574K | 556K | 701K | 578K |
| Gross Profit | (574K) | (556K) | (701K) | (578K) |
| Gross Margin | — | — | — | — |
| Research & Development | 26.57M | 49.12M | 67.82M | 137.77M |
| Selling, General & Admin | 4.1M | 7.61M | 14.42M | 30.73M |
| Operating Expenses | 30.67M | 56.73M | 82.25M | 168.51M |
| Depreciation & Amortization | 574K | 556K | 701K | 578K |
| EBITDA | (29.44M) | (55.15M) | (76.88M) | (160.57M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (31.25M) | (57.28M) | (82.95M) | (169.08M) |
| Operating Margin | — | — | — | — |
| Interest Income | 429K | 1.1M | 4.5M | 5.52M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.23M | 1.57M | 5.37M | 7.93M |
| Income Before Tax | (30.02M) | (55.71M) | (77.58M) | (161.15M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (30.02M) | (55.71M) | (77.58M) | (161.15M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.72) | (1.34) | (1.87) | (3.66) |
| EPS (Diluted) | (0.72) | (1.34) | (1.87) | (3.66) |
| Weighted Avg Shares | 41.43M | 41.43M | 41.43M | 44.02M |
| Weighted Avg Shares (Diluted) | 41.43M | 41.43M | 41.43M | 44.02M |
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.